4//SEC Filing
TAYTON-MARTIN HELEN KATRINA 4
Accession 0001104659-19-001303
CIK 0001621227other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 9:01 PM ET
Size
8.6 KB
Accession
0001104659-19-001303
Insider Transaction Report
Form 4
TAYTON-MARTIN HELEN KATRINA
Chief Operating Officer
Transactions
- Award
Option to purchase Ordinary Shares
2019-01-04+224,724→ 224,724 totalExercise: $0.00Exp: 2029-01-04→ Ordinary Shares (224,724 underlying) - Award
Option to purchase Ordinary Shares
2019-01-04+1,006,224→ 1,006,224 totalExercise: $0.89Exp: 2029-01-04→ Ordinary Shares (1,006,224 underlying)
Footnotes (4)
- [F1]The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 251,556 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 20,958 Ordinary Shares on the fourth of each month from February 4, 2020 through December 2, 2022 and 21,138 Ordinary Shares on January 4, 2023.
- [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Exercisable as to 56,178 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 56,178 Ordinary Shares on January 4, 2021 and January 4, 2022, and 56,190 Ordinary Shares on January 4, 2023.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
Related Parties
1- filerCIK 0001661780
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 9:01 PM ET
- Size
- 8.6 KB